Skip to content
Menu

Nicotinamide Riboside (NR) Dosage: What the Trials Used

NR studies have tested 100–3,000 mg/day in different populations and timeframes. Compare the doses, safety limits and why trial dosing is not personal advice.

By Marcus HaleLongevity Research Editor
Updated

3 min read · 4 sources

On this page

Nicotinamide riboside (NR) trials have tested more than the often-quoted 250–1,000 mg/day range. Published studies include 100–1,000 mg/day for eight weeks in overweight adults, 1,000 mg/day for six weeks in older adults, and 3,000 mg/day for four weeks in a small Parkinson's safety trial 123. These are different research settings, not interchangeable consumer dose recommendations.

The useful question is what each dose was tested to do, in whom, and for how long. Researchers measured whether blood NAD+ went up, tolerability and sometimes disease-specific outcomes. A dose that changes a biomarker is not automatically a dose that improves health.

Affiliate partner

Willow

NAD+ injection alongside a compounded GLP-1 line

See Willow

What the NR trials actually used

The 2019 NIAGEN trial assigned healthy overweight adults to placebo or 100, 300 or 1,000 mg/day for eight weeks. Blood NAD+ increased in a dose-dependent pattern; the investigators reported good tolerability over that period 1. Eight weeks should not be read as evidence of safety over decades.

A separate crossover study in healthy middle-aged and older adults used 500 mg twice daily — 1,000 mg/day — for six weeks. It raised blood NAD+ and was well tolerated, but was not designed to identify a universal maintenance dose 2.

The NR-SAFE trial tested 1,500 mg twice daily — 3,000 mg/day — for four weeks in 20 people with Parkinson's disease. Ten received NR and ten placebo. There were no moderate or severe adverse events, and no significant difference in mild events. This small, monitored safety study supports further research; it does not establish that 3,000 mg/day is safe indefinitely or an appropriate wellness dose 3.

A long-COVID trial used 2,000 mg/day, with one group receiving NR for 20 weeks. It raised NAD+ but did not establish an overall cognitive or symptom benefit over the placebo comparison. That separates a longer exposure record from proof of efficacy 4.

NR trial doses

Swipe table to compare all columns →

StudyDaily NRStudy context
NIAGEN dose-ranging trial100 / 300 / 1,000 mgEight weeks; overweight adults
Older-adult crossover trial1,000 mgSix weeks; blood NAD+ and tolerability
NR-SAFE3,000 mgFour weeks; 20 people with Parkinson’s
Long-COVID trial2,000 mgUp to 20 weeks of NR; biomarker rise, no established overall symptom benefit
Dose, study population and observation time must be read together. These protocols are not personalized recommendations.

Label doses and research doses answer different questions

A product label describes that product's serving. A research protocol describes an intervention for a particular study population. Neither comparison tells an individual to multiply capsules until they match the largest published number.

For a product-specific assessment, our Tru Niagen review examines the offer and evidence. The NMN vs NR comparison explains why the two precursors and their trial doses should not be treated as equivalent.

More is not an established route to better results

The eight-week dose-ranging study found larger blood NAD+ increases at higher NR doses 1. That is a biomarker dose response. It does not establish that escalating a healthy person's daily dose produces more energy, slower aging or longer life. The disease-specific studies also cannot be converted into a general longevity prescription.

Read the nicotinamide riboside benefits evidence alongside the nicotinamide riboside side effects. Small trials can miss uncommon adverse effects, and short exposure cannot settle long-term safety.

How to read the dose

A research dose is not a personal target

  • Read the study duration and population alongside the dose.
  • A biomarker response does not establish a larger health benefit.
  • A small safety trial cannot rule out uncommon or long-term harms.
  • Do not use a calculator to choose a medical dose.

Is there an optimal long-term dose?

There is no validated universal NR maintenance dose for healthy aging. The studies above differ in population, duration, outcome and monitoring. They do not establish which dose should be taken for years, nor that a consumer should pursue the highest possible NAD+ reading.

Discuss supplementation and any dose change with a clinician, particularly when taking medicines or managing a medical condition. Our NAD+ and NMN dosage guide puts route-specific numbers in context; the calculators and tools can help compare quantities and costs, but cannot choose a medically appropriate dose.

Key points

  • NR research includes 100–3,000 mg/day, with substantially different study durations and participants 123.
  • The 3,000 mg/day finding is a four-week safety observation in 20 Parkinson's participants, not proof of lifelong safety 3.
  • Raising blood NAD+ does not establish a larger health benefit or an optimal personal dose.

These are descriptions of published research, not instructions to start or increase NR.

Frequently asked questions

What NR doses have human trials tested?

Published protocols include 100, 300 and 1,000 mg/day for eight weeks in overweight adults; 1,000 mg/day for six weeks in older adults; 2,000 mg/day in a long-COVID trial; and 3,000 mg/day for four weeks in 20 people with Parkinson’s. These settings do not establish a personal recommended dose.

Is 3,000 mg/day of NR proven safe long term?

No. NR-SAFE observed 20 Parkinson’s participants for four weeks, with 10 receiving 3,000 mg/day. No moderate or severe adverse events occurred, but that small, short trial cannot establish indefinitely safe use or rule out uncommon harms.

Does a higher NR dose give more benefit?

Higher doses can produce larger blood NAD+ increases, but that does not establish better energy, healthy-aging or longevity outcomes. The trials do not define a universal optimal dose.

Is the Tru Niagen serving too low compared with research doses?

A product serving and a clinical research protocol answer different questions. A larger study dose is not a reason to multiply capsules. Review the current product label and discuss individual use with a clinician.

What is the optimal long-term NR dose?

No universal maintenance dose for healthy aging has been validated. Study duration, population, medicines and medical history matter; the published maximum is not a personal target.

References

  1. Conze D, Brenner C, Kruger CL (2019). Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/31278280/
  2. Martens CR, Denman BA, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/29599478/
  3. Berven H, Kverneng S, Sheard E, et al. (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. Nature Communications. https://www.nature.com/articles/s41467-023-43514-6
  4. Wu CY, Reynolds WC, Abril I, et al. (2025). Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. EClinicalMedicine. https://pubmed.ncbi.nlm.nih.gov/41357333/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Related reading